UBS Upgrades CVS Health to Buy with Price Target of $79

CVS Health has been upgraded to Buy from Neutral by UBS analyst Kevin Caliendo with a price target of $79, up from $67. The company has shown strong execution and early signs of success in its healthcare benefits segment fixes. UBS sees annual earnings growth of 14% through 2028 for CVS, above the consensus estimate of 12%. The analyst views the valuation as compelling at current share levels.

UBS analyst Kevin Caliendo has upgraded CVS Health (CVS) to a "Buy" rating from "Neutral," with a price target of $79, up from $67. The upgrade reflects strong execution and early signs of success in the company's healthcare benefits segment fixes [1].

Caliendo expects CVS to achieve annual earnings growth of 14% through 2028, which is above the consensus estimate of 12%. The analyst believes the current valuation of the stock is compelling at its current share levels. The upgrade comes after CVS reported earnings of $1.81 per share for the last quarter, surpassing the consensus estimate of $1.46, and reported quarterly revenue of $98.92 billion, up 8.4% year-over-year [2].

The upgrade is a significant boost for CVS, which has seen increased interest from institutional investors. Kovitz Investment Group Partners LLC, for instance, grew its holdings in CVS Health by 266.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission [2].

The analyst's positive outlook on CVS Health is likely to attract more investors, given the company's strong financial performance and promising growth prospects. The upgrade also aligns with the broader market sentiment towards the healthcare sector, which has been experiencing robust growth in recent years.

References:
[1] https://finance.yahoo.com/news/cvs-health-upgraded-occidental-downgraded-133333408.html
[2] https://www.marketbeat.com/instant-alerts/filing-kovitz-investment-group-partners-llc-buys-148703-shares-of-cvs-health-corporation-nysecvs-2025-08-15/